Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OraGrowtH210: LUM-201 in Pediatric Growth Hormone Deficiency
NCT04614337Phase 2Completed
- Sponsor
- Lumos Pharma, Inc.
- Start
- Dec 2020
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 2 trial of ibutamoren in growth hormone deficiency (GHD), sponsored by Lumos Pharma, Inc.. Started Dec 2020; status: completed.
02
Drugs
ibutamoren
03
Conditions
growth hormone deficiency (GHD)
Beyond the preview
Go deeper on NCT04614337.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04614337.